{"id":"NCT05044195","sponsor":"Seqirus","briefTitle":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","officialTitle":"A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison With a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-30","primaryCompletion":"2022-01-18","completion":"2022-09-09","firstPosted":"2021-09-14","resultsPosted":"2023-09-28","lastUpdate":"2023-09-28"},"enrollment":2044,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza, Human"],"interventions":[{"type":"BIOLOGICAL","name":"aQIV","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator QIV","otherNames":[]}],"arms":[{"label":"aQIV","type":"EXPERIMENTAL"},{"label":"Comparator QIV","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.","primaryOutcome":{"measure":"Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains","timeFrame":"Day 22","effectByArm":[{"arm":"aQIV","deltaMin":731.9,"sd":null},{"arm":"Comparator QIV","deltaMin":586.85,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["United States","Estonia","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":1027},"commonTop":["Injection site pain","Fatigue","Headache","Arthralgia","Myalgia"]}}